The first of two trials of an FDA-approved new class of antidepressants for women will start in Baltimore in the coming weeks.
The second trial, to be run in the Atlanta metro area, will start later this year in a small community center, according to the Food and Drug Administration.
The trials, led by researchers at Johns Hopkins University, will enroll women who have experienced symptoms associated with endometriosis and other conditions that affect ovulation.
Women who receive the drugs in this trial will be able to use them for the first time within 24 hours of a diagnosis of endometrial cancer.
They will be required to take a pill twice a day for up to two months before the trial can begin.
In a statement, the FDA said that it is committed to working with scientists and clinical researchers to improve the use of drugs to treat ovarian cancer, ovarian disorders and ovarian cancer.
The agency has a plan to address this need through the development of a prescription-only program for drugs that treat endometrium, the agency said.
The FDA did not say how many women would be enrolled.
A previous FDA plan to expand the program, known as the FDA-sponsored Endometrial Cancer Program, would have allowed patients to take an additional 30 to 60 pills a day.